2026-06-05T18:06:57Zhttps://riuma.uma.es/rest/oai/request

oai:riuma.uma.es:10630/295442026-02-03T11:27:03Zcom_10630_2254col_10630_37953

00925njm 22002777a 4500 dc Sánchez-Muñoz, Alfonso author Gallego-Domínguez, Elena María author De Luque, Vanessa author Pérez-Rivas, Luis G. author Vicioso-Recio, Luis Prudencio author Ribelles, Nuria author Lozano-Castro, José author Alba-Conejo, Emilio author 2010-04-13 Background: Mutational analysis of the KRAS gene has recently been established as a complementary in vitro diagnostic tool for the identification of patients with colorectal cancer who will not benefit from anti-epidermal growth factor receptor (EGFR) therapies. Assessment of the mutation status of KRAS might also be of potential relevance in other EGFR-overexpressing tumors, such as those occurring in breast cancer. Although KRAS is mutated in only a minor fraction of breast tumors (5%), about 60% of the basal-like subtype express EGFR and, therefore could be targeted by EGFR inhibitors. We aimed to study the mutation frequency of KRAS in that subtype of breast tumors to provide a molecular basis for the evaluation of anti-EGFR therapies. Methods: Total, genomic DNA was obtained from a group of 35 formalin-fixed paraffin-embedded, triple-negative breast tumor samples. Among these, 77.1% (27/35) were defined as basal-like by immunostaining specific for the established surrogate markers cytokeratin (CK) 5/6 and/or EGFR. KRAS mutational status was determined in the purified DNA samples by Real Time (RT)-PCR using primers specific for the detection of wild-type KRAS or the following seven oncogenic somatic mutations: Gly12Ala, Gly12Asp, Gly12Arg, Gly12Cys, Gly12Ser, Gly12Val and Gly13Asp. Results: We found no evidence of KRAS oncogenic mutations in all analyzed tumors. Conclusions: This study indicates that KRAS mutations are very infrequent in triple-negative breast tumors and that EGFR inhibitors may be of potential benefit in the treatment of basal-like breast tumors, which overexpress EGFR in about 60% of all cases. Sánchez-Muñoz A, Gallego E, de Luque V, Pérez-Rivas LG, Vicioso L, Ribelles N, Lozano J, Alba E. Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer. BMC Cancer. 2010 Apr 13;10:136. doi: 10.1186/1471-2407-10-136. PMID: 20385028; PMCID: PMC2868051. https://hdl.handle.net/10630/29544 10.1186/1471-2407-10-136 Cáncer - Aspectos genéticos Mamas - Cáncer - Aspectos genéticos Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer.